Edward A. Pesicka's departure as Chief Executive Officer of Accendra Health Inc/Va/ was reported; the filing names no successor. As of November 6, 2026, Accendra Health Inc/Va/ has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 15, 2026 to November 3, 2026, naming 1 departure (Form 8-K, August 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Accendra Health Inc/Va/? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-03
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-09-28
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-17
- · In / out: Out · Person: Edward A. Pesicka · Role: Chief Executive Officer · 8-K, 2026-08-10
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-15
Accendra Health Inc/Va/ reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-15 to 2026-11-03. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Accendra Health Inc/Va/ files it.
Also on the record for Accendra Health Inc/Va/
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 10.8% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4.75% of the class | 5%+ stakes | Source |
| March 30, 2026 | Stake report, Schedule 13G, by Kevin M. Webb | 5.61% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G, by CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 5.24% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13D, by Coliseum Capital Management, LLC | 16.9% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.71% of the class | 5%+ stakes | Source |
| October 9, 2025 | Stake report, Schedule 13G/A, by Dimensional Fund Advisors LP | 4.5% of the class | 5%+ stakes | Source |
| October 2, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Accendra Health Inc/Va/ now and the warning signs.
Free to see. No signup.
Keep reading
More on Accendra Health Inc/Va/ and the records around it.
Accendra Health Inc/Va/ elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Coliseum Capital Management, LLC also filed stake reports on 6 other companies: Herc Holdings Inc. (Aug 2026), MasterBrand, Inc. (Aug 2026), Sonos, Inc. (Aug 2026)
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC also filed stake reports on 12 other companies: HAIN CELESTIAL GROUP INC (Aug 2026), MEDIFAST INC (Aug 2026), Service Properties Trust (Aug 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
Watch Accendra Health Inc/Va/
Get an email when Accendra Health Inc/Va/ files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Accendra Health Inc/Va/?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Accendra Health Inc/Va/: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Accendra Health Inc/Va/ covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | Reported | not named in the filing | 8-K, 2026-11-03 | ||
| 2026-09-28 | Reported | not named in the filing | 8-K/A, 2026-09-28 | ||
| 2026-09-17 | Reported | not named in the filing | 8-K, 2026-09-17 | ||
| 2026-08-10 | Out | Chief Executive Officer | 8-K, 2026-08-10 | ||
| 2026-05-15 | Reported | not named in the filing | 8-K, 2026-05-15 |
Who leads Accendra Health Inc/Va/, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Edward A. Pesicka, departure reported (filed 2026-08-10). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Accendra Health Inc/Va/: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Accendra Health Inc/Va/, with the record behind each one.
Find candidates like Chief Executive Officer at Accendra Health Inc/Va/Every change, in the filing's words
Reported
On October 29, 2026, Perry A. Bernocchi, the Company's Executive Vice President, Chief Operating Officer, entered into a transition agreement with the Company under which Mr. Bernocchi will cease to be an executive officer and will serve as Strategic Advisor to the Chief Executive Officer until December 31, 2026, unless his employment ends earlier.
- During this period, he will keep his current base salary and remain eligible for his 2026 annual bonus at his current target.
- He will also remain eligible for severance under the Company's Officer Severance Policy or his change of control severance agreement, as applicable, subject to the terms of those arrangements.
Reported
to report that, on that date, Accendra Health announced that it named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer.
- Other disclosures in the original filing are unchanged.
- On September 22, 2026, Accendra Health and Mr. Gardner-Smith, the Company's next President and Chief Executive Officer, mutually agreed to an effective start date of October 5, 2026.
- Edward A. Pesicka, who previously announced his intent to retire in August, will remain in the role of President and Chief Executive Officer until Mr. Gardner-Smith assumes the role on October 5, 2026, at which point Mr. Pesicka will also retire from the Board of Directors, as previously announced.
- On September 28, 2026, Mr. Pesicka and the Company entered into a consulting agreement, under which Mr. Pesicka will serve as an advisor to the Company for up to thirty months to ensure a smooth transition.
- Under the consulting agreement, Mr. Pesicka's previously awarded outstanding equity awards shall remain outstanding and shall continue to vest in accordance with their existing terms during the term of the consulting arrangement.
- Additionally, Mr. Pesicka will receive a COBRA benefit, as described in the consulting agreement.
Reported
On September 17, 2026, Accendra Health, Inc. (the "Company" or "Accendra Health") announced that it named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer.
- Mr. Gardner-Smith, who has served on the Company's Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026.
- He will succeed Edward A. Pesicka, who previously announced his intent to retire in August.
- Mr. Pesicka will remain in the role of President and CEO until Mr. Gardner-Smith assumes the role, at which point Mr. Pesicka will also retire from the Board of Directors, as previously announced.
- Mr. Pesicka will continue to serve as an advisor to Mr. Gardner-Smith and the Company's leadership team to ensure a smooth transition.
- Mr. Gardner-Smith will continue to serve on the Accendra Health Board of Directors and the Board's Executive Committee as a non-independent director and will step down from his roles on the Our People & Culture and Audit Committees of the Board.
- These roles will be filled by an independent Board member.
- On September 16, 2026, the Company entered into an offer letter with Mr. Gardner-Smith describing the terms of his employment with Accendra Health (the "Offer Letter").
Departing: Edward A. Pesicka, Chief Executive Officer
On August 10, 2026, Accendra Health, Inc. (the "Company") announced that Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, notified the board of directors (the "Board") of the Company of his intention to retire and step down from the Board by the end of 2026, or such earlier time as a successor is appointed.
- Mr. Pesicka's decision to retire is not the result of any disagreement with the Company regarding any matter relating to the Company's operations, policies or practices.
- The Board has commenced a process to evaluate and select the candidate to succeed Mr. Pesicka.
Reported
Each equity grant made pursuant thereto will be evidenced by an agreement between the Company and the person named therein.
- On May 14, 2026 at the 2026 Annual Meeting of Shareholders (the "Annual Meeting") of Accendra Health, Inc. (the "Company"), the shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan (the "Amended and Restated 2023 Plan") which amends and restates the Owens & Minor, Inc. 2023 Omnibus Incentive Plan (as amended as of March 14, 2024).
- Under the terms of the Amended and Restated 2023 Plan, the Board of Directors (the "Board") has authorized the Our People & Culture Committee of the Board to grant equity and other incentive awards to employees, non-employee directors and consultants.
Tools for this story
Each opens in a new tab, filled in for Accendra Health Inc/Va/. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.